Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2019 August;110(4) > Minerva Medica 2019 August;110(4):330-40

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  UPDATES IN OVARIAN CANCER AND SECONDARY PERITONEAL TUMORS 

Minerva Medica 2019 August;110(4):330-40

DOI: 10.23736/S0026-4806.19.06078-6

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis

Benito CHIOFALO 1 , Simone BRUNI 2, Camilla CERTELLI 1, Isabella SPERDUTI 3, Ermelinda BAIOCCO 1, Enrico VIZZA 1

1 Unit of Gynecologic Oncology, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy; 2 Division of Obstetrics and Gynecology, Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy; 3 Unit of Biostatistical, IRCCS Regina Elena National Cancer Institute, Rome, Italy



INTRODUCTION: Epithelial ovarian cancer (EOC) is the seventh most common cancer among women in the world and the leading cause of death from gynecological malignancies. The standard treatment for advanced EOC consists of optimal primary debulking surgery (PDS) associated with an adjuvant chemotherapy. Neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) have been proposed in the management of advanced EOC to increase the rate of complete citoreductive surgery and to reduce morbidity and mortality. This systematic review and meta-analysis is conducted to compare the oncologic and postoperative outcomes of NACT and IDS with PDS followed by chemotherapy in patients with ovarian cancer.
EVIDENCE ACQUISITION: We conducted a search on the electronic databases PubMed/Medline, Cochrane and Scopus. All randomized controlled trials, cohort and case-control studies comparing PDS and IDS in ovarian cancer published in English until 28 February 2019 were considered eligible.
EVIDENCE SYNTHESIS: Twenty studies were included in the systematic review. As regards the meta-analysis, only studies that allowed the data we needed to be extracted were included: five were included for the evaluation of overall survival (OS) and PFS and 9 for the evaluation of major postoperative complications and days of hospital stay.
CONCLUSIONS: From the meta-analysis of the current available literature, none of the two investigated procedures has proven to be superior in terms of OS and PFS in the treatment of advanced ovarian cancer. However surgical complexity and postoperative complications are reduced in the IDS group.


KEY WORDS: Ovarian neoplasms; Cytoreduction surgical procedures; Neoadjuvant therapy; Drug therapy

inizio pagina